Advanced in Multiple System Atrophy

Dr. Rajesh B. Pahwa

Neurology
Kansas University Physicians Inc
3901 Rainbow Blvd, Suite 5300, 
Kansas City, KS 
Accepting New Patients
Offers Telehealth
Advanced in Multiple System Atrophy
Kansas University Physicians Inc
3901 Rainbow Blvd, Suite 5300, 
Kansas City, KS 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Rajesh Pahwa is a Neurologist in Kansas City, Kansas. Dr. Pahwa is rated as an Advanced provider by MediFind in the treatment of Multiple System Atrophy. His top areas of expertise are Parkinson's Disease, Movement Disorders, Essential Tremor, Deep Brain Stimulation, and Thalamotomy. Dr. Pahwa is currently accepting new patients.

His clinical research consists of co-authoring 155 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Multiple System Atrophy.

Specialties
Neurology
Licenses
Psychiatry & Neurology in KS
Hospital Affiliations
Adventhealth Shawnee Mission
Kansas City Orthopaedic Institute
Lmh
University Of Kansas Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Cox Health
  • EPO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
Sunflower Health Plan
  • HMO
  • MANAGED MEDICAID PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

KANSAS UNIVERSITY PHYSICIANS INC
3901 Rainbow Blvd, Suite 5300, Kansas City, KS 66160
Other Locations
KANSAS UNIVERSITY PHYSICIANS INC
3599 Rainbow Blvd, Kansas City, KS 66103
KANSAS UNIVERSITY PHYSICIANS INC
4000 Cambridge St, Kansas City, KS 66160

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Randomized, Sham Surgery Controlled, Double-blind, Multi-center, Phase 1 Clinical Trial, Evaluating the Safety of VY-AADC02 in Moderate to Advanced Parkinson's Disease Patients With Motor Fluctuations
A Randomized, Sham Surgery Controlled, Double-blind, Multi-center, Phase 1 Clinical Trial, Evaluating the Safety of VY-AADC02 in Moderate to Advanced Parkinson's Disease Patients With Motor Fluctuations
Enrollment Status: Completed
Publish Date: December 10, 2024
Intervention Type: Biological, Other
Study Drug: VY-AADC02
Study Phase: Phase 1
A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of CVN424 in Parkinson's Disease Patients With Motor Fluctuations
A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of CVN424 in Parkinson's Disease Patients With Motor Fluctuations
Enrollment Status: Completed
Publish Date: July 03, 2024
Intervention Type: Drug
Study Drug: CVN424
Study Phase: Phase 2
A Multi-Center, Single-Dose, Multiple-Dose, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered ENT-01 for the Treatment of Parkinson's Disease Related Constipation
A Multi-Center, Single-Dose, Multiple-Dose, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered ENT-01 for the Treatment of Parkinson's Disease Related Constipation
Enrollment Status: Completed
Publish Date: December 27, 2023
Intervention Type: Other, Drug
Study Phase: Phase 1/Phase 2
Parkinson's Foundation: PD Generation: Mapping the Future of Parkinson's Disease
Parkinson's Foundation: PD Generation: Mapping the Future of Parkinson's Disease
Enrollment Status: Unknown
Publish Date: July 14, 2023
Intervention Type: Device
Study Phase: Not Applicable
A Double-Blind, Placebo-Controlled 16-Week Study of the Cognitive Effects of Oral p38 Alpha Kinase Inhibitor Neflamapimod in Dementia With Lewy Bodies (DLB)
A Double-Blind, Placebo-Controlled 16-Week Study of the Cognitive Effects of Oral p38 Alpha Kinase Inhibitor Neflamapimod in Dementia With Lewy Bodies (DLB)
Enrollment Status: Completed
Publish Date: June 29, 2023
Intervention Type: Drug
Study Drug: Neflamapimod
Study Phase: Phase 2
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study, With an Active-Treatment Dose-Blinded Period, to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Subjects With Parkinson's Disease
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study, With an Active-Treatment Dose-Blinded Period, to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Subjects With Parkinson's Disease
Enrollment Status: Terminated
Publish Date: February 28, 2022
Intervention Type: Drug
Study Drug: BIIB054
Study Phase: Phase 2
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of CX-8998 for Essential Tremor
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of CX-8998 for Essential Tremor
Enrollment Status: Completed
Publish Date: November 23, 2021
Intervention Type: Drug
Study Phase: Phase 2
Effect of LY3154207 on Cognition in Mild-to-Moderate Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB)
Effect of LY3154207 on Cognition in Mild-to-Moderate Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB)
Enrollment Status: Completed
Publish Date: July 23, 2021
Intervention Type: Drug
Study Phase: Phase 2
Safety and Efficacy of THN102 in Patients With Parkinson's Disease and Excessive Daytime Sleepiness
Safety and Efficacy of THN102 in Patients With Parkinson's Disease and Excessive Daytime Sleepiness
Enrollment Status: Completed
Publish Date: December 01, 2020
Intervention Type: Drug
Study Phase: Phase 2
A 4-Week, Double-blind, Placebo-controlled, Randomized, Multicenter, Crossover Study of the Safety, Efficacy, and Pharmacokinetics of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate Hydrochloride] in Subjects With Parkinson's Disease and Excessive Sleepiness
A 4-Week, Double-blind, Placebo-controlled, Randomized, Multicenter, Crossover Study of the Safety, Efficacy, and Pharmacokinetics of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate Hydrochloride] in Subjects With Parkinson's Disease and Excessive Sleepiness
Enrollment Status: Completed
Publish Date: January 09, 2020
Intervention Type: Drug, Other
Study Phase: Phase 2
SYN120 a Dual 5-HT6/5-HT2A Antagonist Proof of Concept Study to Evaluate Its Safety, Tolerability and Efficacy in Parkinson's Disease Dementia (SYNAPSE)
SYN120 a Dual 5-HT6/5-HT2A Antagonist Proof of Concept Study to Evaluate Its Safety, Tolerability and Efficacy in Parkinson's Disease Dementia (SYNAPSE)
Enrollment Status: Completed
Publish Date: April 19, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 10 Less Clinical Trials

155 Total Publications

Transcutaneous Peripheral Nerve Stimulation for Essential Tremor: A Randomized Clinical Trial.
Transcutaneous Peripheral Nerve Stimulation for Essential Tremor: A Randomized Clinical Trial.
Journal: JAMA neurology
Published: October 20, 2025
Similar Doctors
Experienced in Multiple System Atrophy
Dr. Ka K. Au
Neurology
Experienced in Multiple System Atrophy
Dr. Ka K. Au
Neurology

Kansas University Physicians Inc

4000 Cambridge St, 
Kansas City, KS 
 (0.2 miles away)
913-588-1227
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Ka Au is a Neurologist in Kansas City, Kansas. Dr. Au is rated as a Distinguished provider by MediFind in the treatment of Multiple System Atrophy. His top areas of expertise are Movement Disorders, Parkinson's Disease, Essential Tremor, Secondary Parkinsonism, and Deep Brain Stimulation. Dr. Au is currently accepting new patients.

Experienced in Multiple System Atrophy
Dr. Arpan M. Patel
Neurology
Experienced in Multiple System Atrophy
Dr. Arpan M. Patel
Neurology

Kansas University Physicians Inc

4000 Cambridge St, 
Kansas City, KS 
 (0.2 miles away)
913-588-1227
Languages Spoken:
English, Hindi
See accepted insurances
Accepting New Patients
Offers Telehealth

Arpan Patel is a Neurologist in Kansas City, Kansas. Dr. Patel is rated as an Advanced provider by MediFind in the treatment of Multiple System Atrophy. His top areas of expertise are Rasmussen Encephalitis, Anti-NMDA Receptor Encephalitis, Syringobulbia, and Encephalitis. Dr. Patel is currently accepting new patients.

Experienced in Multiple System Atrophy
Dr. Jeffrey P. Halladay
Neurology
Experienced in Multiple System Atrophy
Dr. Jeffrey P. Halladay
Neurology

Lawrence Physicians LLC

1130 W 4th St, 3203 Lawrence Neurology Sp, 
Lawrence, KS 
 (34.7 miles away)
785-830-8324
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Jeffrey Halladay is a Neurologist in Lawrence, Kansas. Dr. Halladay is rated as an Advanced provider by MediFind in the treatment of Multiple System Atrophy. His top areas of expertise are Movement Disorders, Parkinson's Disease, Migraine, and Essential Tremor. Dr. Halladay is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Pahwa's expertise for a condition
ConditionClose
View All 13 Advanced Conditions
View All 33 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile